Back to Agenda
Is the Future Bright for Treatment of Neurodegenerative Diseases?
Session Chair(s)
Susan Yule
Senior Global Regulatory Leader, F. Hoffmann-La Roche Ltd., Switzerland
Despite decades of research, we continue to search for meaningful treatment in neurodegenerative diseases such as Alzheimer's and Parkinson's. This session will focus on the impact of patient associations on the progress of treatment. A case study will be explored.
Learning Objective : Discuss where we are today and what is the future in treatment of diseases such as Alzheimer's or Parkinson's; Describe the impact the associations have had in improving treatment.
Speaker(s)
Conrad Hawkins
Associate Consultant, KMR Group Inc., United States
Recent Approaches and the Future of Neurodegenerative Diseases
Laura Gault, MD, PHD
Group Project Leader, AbbVie, Inc., United States
Challenges in Drug Development of Disease Modifying Drugs in Alzheimer's Disease
Juan Garcia-Burgos, MD, PHD
Head of Public and Stakeholders Engagement Department, European Medicines Agency, Netherlands
How Patients Can Help Regulators to Bring New Treatments for Neurodegenerative Diseases?
Jamie A. Mullen, MD
Global Clinical Leader, AstraZeneca, United States
Industry Perspective
Have an account?